# Keynatinib in Treated Patients With NSCLC and Brain Metastases

> **NCT04824079** · PHASE2 · COMPLETED · sponsor: **Medolution Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer With EGFR Mutation
- Brain Metastases

## Interventions

- **DRUG:** Keynatinib

## Key facts

- **NCT ID:** NCT04824079
- **Lead sponsor:** Medolution Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2024-12-10
- **Final completion:** 2024-12-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824079, "Keynatinib in Treated Patients With NSCLC and Brain Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04824079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*